out with water after inhalations) Headache Often mild, and usually disappear as the medication continues to be used: Heart palpitations Trembling Uncommon (up to 1 in 100 people) Feeling restlessness, nervous, or agitated Disturbed sleep Feeling dizzy Nausea Tachycardia (fast heart rate) Bruising of the skin Muscle cramps Rare (up to 1 in 1,000 people) Rash Itchiness Bronchospasm (tightening of the muscles in the airways causing wheezing immediately after use of the medication, which is possibly sign of an allergic reaction and should be met with immediate medical attention) Hypokalemia (low levels of potassium in the blood) Heart arrhythmia Very rare (up to 1 in 10,000 people) Depression Changes in behaviour, especially in children Chest pain or tightness in chest Increase in blood glucose levels Taste changes, such as an unpleasant taste in the mouth Changes in blood pressure Other With high doses for a long period of time. Reduced bone mineral density, causing osteoporosis Cataracts Glaucoma Slowed rate of growth in children and adolescents Dysfunction of the adrenal gland, which affects the production of various hormones Allergic reaction Angioedema (swelling of the face, mouth, tongue, and/or throat. Difficulty swallowing. Hives. Difficulty breathing. Feeling of faintness) Bronchospasm (sudden acute wheezing or shortness of breath immediately after use of medication. The patient should use their reliever medication immediately.) Society and culture Legal status It was approved for use in the United States in July 2006. Budesonide/formoterol was approved for use in the European Union in April 2014. There are several patents related to the drug; some of which have expired. It was initially marketed by AstraZeneca. References External links Combination drugs Respiratory agents AstraZeneca brands World Health Organization essential medicines Wikipedia medicine articles ready to translate